(Legal Newsline) - The Federal Trade Commission (FTC) announced March 28 that DaVita
Inc., a national outpatient kidney-dialysis chain, will divest ownership
interest in seven clinics in order to complete its $358 million acquisition of
competitor Renal Ventures Management LLC.
the United States’ second largest provider of outpatient dialysis services,
while Renal Ventures is the seventh largest.
The FTC alleged a merger
between the two companies would lead to significant anti-competitive effects in different U.S. markets. These markets include Brick, Clifton, Somerville,
Succasunna and Trenton in New Jersey, as well as Denton and Frisco in Dallas.
The merger would cause either a monopoly or a reduction of competitors from
three to two in those markets, according to the FTC.
the allegations, DaVita will divest a clinic in each of the affected markets --
five in New Jersey and two in Dallas.
voted 2-0 to issue the complaint and accept the proposed consent order, which
is currently subject to public comment until April 27. After the public comment
period, the FTC will decide whether to finalize the order.